| Jul 18 |
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
|
| Jul 9 |
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
|
| Jul 5 |
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
|
| Jul 1 |
Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
|
| Jun 28 |
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
|
| Jun 28 |
Apellis falls as EU experts decline to back eye disorder therapy
|
| Jun 28 |
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
|
| Jun 19 |
Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week
|
| Jun 11 |
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
|
| Jun 10 |
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
|
